Browsing “September, 2020 | EVERSANA”

EVERSANA Hosts Expert Roundtable: The U.S. Pharmaceutical Market Outlook

Join Dr. Kathleen Sebelius, Former United States Secretary of Health and Human Services; Joe Jimenez, Former CEO of Novartis and Co-Founder & Managing Director of Aditum Bio; Kabir Nath, President and CEO of Otsuka North America; and Jim Lang, EVERSANA’s CEO, at our expert virtual roundtable on October 29, 2020 at 4 PM CET, 3 PM […]

California to Produce Own Generics to Lower Prescription Drug Costs

Country: UNITED STATES | Region: NORTH AMERICA | Type: Policy | Keywords: #calrx #essentialmedicines #generics #hhs #prescriptiondrugs #sb852 #statedruglabel PRICENTRIC BRIEF: California Governor Gavin Newsom has signed legislation aimed at bringing down the cost of prescription drugs for taxpayers, employers, and consumers in California by teaming up with manufacturers to produce and distribute generic prescription drugs Under SB 852, California will create Cal Rx, […]

Palette Life Sciences Announces Partnership Agreement With EVERSANA to Support US Commercialization of Solesta™

Agreement outlines commercialization and distribution services to enhance market access for patients diagnosed with fecal incontinence SANTA BARBARA, CALIF. AND STOCKHOLM – September 28, 2020 – Palette Life Sciences, a fully integrated life sciences company, today announced it has partnered with EVERSANA™, a leading provider of commercial services to the life science industry, to enhance […]

PPMA 2020 Insights: Trends in HTA Decisions

Country: THE NETHERLANDS | Region: EUROPE | Type: PPMA 2020 Insights PRICENTRIC BRIEF: At PPMA 2020, EVERSANA’s Dr. Magdi Stino and Alan Crowther came together to detail some recent trends and share approaches for using Health Technology Assessment (HTA) data when decision making, leveraging information from the Pricentric HTA database   Looking specifically at the UK, Germany, France, Canada, and Brazil, Dr. Stino went on to assess the recommendation types for all […]

EVERSANA Sponsors the Orphan Drugs & Rare Diseases Congress Series

EVERSANA is proud to be a Global Sponsor at this year’s Orphan Drugs & Rare Diseases Congress series to provide a comprehensive overview of the critical issues shaping the future of 0rphan drugs. We are on a mission to advance the drug development and commercialization of orphan drugs. Together with our clients, we aim to […]

Switzerland’s Journey to Introducing Confidential Managed-Entry Agreements

Country: SWITZERLAND | Region: EUROPE | Type: Policy PRICENTRIC BRIEF: Switzerland’s Ministry of the Interior has introduced a new law, dubbed “Modèles de Prix Pour Médicaments”, which aims to establish a legal basis for the use of confidential market-access schemes to improve patient access to innovative medicines It is also introducing cost-containment measures for the compulsory health insurance scheme (AOS), dictating, for […]


ADVANCING THE COMMERCIALIZATION OF DIGITAL THERAPEUTICS Join EVERSANA at a number of virtual events as we work to advance the commercialization of digital medicines. “While advancements in digital medicine take us into a new frontier, these devices can and should be available through existing prescription, distribution and reimbursement infrastructures. The commercial model for digital medicine […]

EVERSANA launches ACTICS by EVERSANA™, the technology-enabled solution combining predictive analytics integrated with real-time commercial services to drive next best action in the life science sector

CHICAGO – September 16, 2020 – EVERSANA™, the leading provider of global commercial services to the life sciences industry, today launched ACTICS by EVERSANA™, the technology-enabled solution to optimize end-to-end commercial success for life science companies. Combining the power of AI-driven predictive analytics with ready-to-deploy, real-time commercial services, ACTICS provides the cloud-based solution pharmaceutical innovators […]

German Payer GKV-SV Concerned Over Added Value of Health Apps

Country: GERMANY | Region: EUROPE | Type: Pricing & Reimbursement | Keywords: #amnog #bfarm #digitalsupplyact #gkvsv #gsv #healthapps #hta #regulation PRICENTRIC BRIEF: While Germany’s umbrella payer, GKV-Spitzenverband (GKV-SV) sees great potential in funding digital health applications, legal funding regulations are a “major problem,” said GKV-SV Board Member, Stefanie Stoff-Ahnis Security, function, quality, data protection and data security of the apps will undergo tests by the Federal Institute for Drugs and Medical […]

EVERSANA Sponsors CBI’s HUB, SPP and e-Services Conference

Accelerating the prescribing process through enhanced access support CBI’s annual Hub and SPP conference is the gold standard event convening key stakeholders – manufacturers, specialty pharmacies, hubs, payers, PBMs and physicians – to explore strategies for developing and integrating hub programs and other patient-centric services to ensure product access and maximized reimbursement. Join the EVERSANA […]